Neurotrope (NTRP) Reaches $4.41 1 Year Low; Ocean Rig Udw (ORIG) Sellers Increased By 5.65% Their Shorts

August 1, 2017 - By Marguerite Chambers

Ocean Rig Udw Incorporated (NASDAQ:ORIG) had an increase of 5.65% in short interest. ORIG’s SI was 5.31M shares in August as released by FINRA. Its up 5.65% from 5.02M shares previously. With 291,600 avg volume, 18 days are for Ocean Rig Udw Incorporated (NASDAQ:ORIG)’s short sellers to cover ORIG’s short positions. About 44,300 shares traded. Ocean Rig UDW Inc. (NASDAQ:ORIG) has declined 87.33% since August 1, 2016 and is downtrending. It has underperformed by 104.03% the S&P500.

The stock of Neurotrope Inc (NASDAQ:NTRP) hit a new 52-week low and has $4.10 target or 7.00% below today’s $4.41 share price. The 8 months bearish chart indicates high risk for the $34.79M company. The 1-year low was reported on Aug, 1 by Barchart.com. If the $4.10 price target is reached, the company will be worth $2.44M less. About 3,899 shares traded. Neurotrope Inc (NASDAQ:NTRP) has 0.00% since August 1, 2016 and is . It has underperformed by 16.70% the S&P500.

Among 7 analysts covering Ocean Rig UDW (NASDAQ:ORIG), 1 have Buy rating, 5 Sell and 1 Hold. Therefore 14% are positive. Ocean Rig UDW had 14 analyst reports since August 10, 2015 according to SRatingsIntel. The stock of Ocean Rig UDW Inc. (NASDAQ:ORIG) earned “Hold” rating by Zacks on Tuesday, August 18. Danske Bank downgraded the shares of ORIG in report on Tuesday, February 9 to “Sell” rating. Danske upgraded the shares of ORIG in report on Monday, August 10 to “Sell” rating. As per Tuesday, August 16, the company rating was downgraded by Deutsche Bank. The firm earned “Underweight” rating on Friday, March 11 by Simmons & Co. As per Friday, March 11, the company rating was downgraded by Piper Jaffray. On Friday, March 11 the stock rating was maintained by Deutsche Bank with “Buy”. Cowen & Co maintained Ocean Rig UDW Inc. (NASDAQ:ORIG) rating on Monday, August 17. Cowen & Co has “Outperform” rating and $8 target.

Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical firm with its product candidates in pre-clinical and clinical development. The company has market cap of $34.79 million. The Firm is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease , which is in the clinical testing stage. It currently has negative earnings. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing.